Tag: KDC-MN-070

Cortexin is a lyophilized complex of water-soluble polypeptide fractions with molecular weights ranging from 1,000 to 10,000 Daltons, obtained by acetic acid extraction from the cerebral cortex of cattle and pigs younger than 12 months of age. The preparation contains predominantly acidic and neutral polypeptides (70 to 95 percent of total mass), free amino acids (including glutamic acid, aspartic acid, glycine, serine, lysine, and alanine as quantitatively predominant species), and trace quantities of vitamins, minerals, and fatty acids. Unlike single-sequence peptide therapeutics, Cortexin is a heterogeneous mixture without a defined primary structure, and its pharmacological activity is attributed to the collective action of multiple bioactive peptide fractions rather than to any single molecular entity.

The compound was developed within the Soviet and subsequently Russian bioregulator research program led by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology beginning in the 1980s, with the first clinical applications in military and aerospace medicine. Cortexin received pharmaceutical registration in the Russian Federation in 1999 and is manufactured by GEROPHARM LLC (Saint Petersburg) as a lyophilisate for intramuscular injection at 5 mg and 10 mg strengths, with glycine (12 mg) as the stabilizing excipient. The compound is registered in Russia, Ukraine, Kazakhstan, Belarus, Uzbekistan, and several other Commonwealth of Independent States jurisdictions for the treatment of acute and chronic cerebrovascular disorders, traumatic brain injury, cognitive impairment, encephalopathy of various origins, epilepsy as adjunctive therapy, and perinatal central nervous system lesions in children. It is not registered or approved in the European Union, the United States, Japan, or any jurisdiction with International Council for Harmonisation regulatory standards.

The molecular mechanisms of Cortexin are pleiotropic and incompletely characterized at the individual peptide level. Demonstrated activities include modulation of glutamatergic transmission through interaction with AMPA receptors, kainate receptors, and metabotropic glutamate receptors (mGluR1 and mGluR5); GABAergic modulation through GABA-A receptor binding; activation of neurotrophic signaling cascades including brain-derived neurotrophic factor and nerve growth factor pathways; antioxidant activity through restoration of pro-oxidant and antioxidant system balance; anti-inflammatory action at both cerebral and systemic levels; and anti-apoptotic effects on neurons under ischemic and excitotoxic stress. Radioactively labeled Cortexin peptides have been demonstrated to cross the blood-brain barrier in mice, supporting direct central nervous system activity. Neuron-specific proteins including beta-5-tubulin, creatine kinase B, and protein 14-3-3 alpha/beta have been identified as molecular partners of Cortexin peptides in brain tissue.

The clinical evidence base for Cortexin is substantial within the Russian-language medical literature but limited in the international peer-reviewed literature. The largest body of evidence supports efficacy in acute ischemic stroke, where Cortexin at 10 mg twice daily intramuscularly for 10 days is included in Russian national clinical practice guidelines. A multicenter randomized controlled study (Fedin et al. 2018) demonstrated dose-dependent effects of Cortexin (10 mg versus 20 mg versus standard care alone) on neurological deficit severity, asthenia, and sleep disturbance in patients with chronic cerebral ischemia, with antioxidant effects confirmed by laboratory markers regardless of dose. A multicenter study of cognitive dysfunction in children demonstrated improvement in attention, visual memory, and thinking in pediatric patients with consequences of perinatal central nervous system lesions. In cerebral palsy with comorbid epilepsy, Cortexin as adjunctive therapy reduced seizure frequency by more than two-fold in 36.9 percent of patients while improving motor function. Comparative preclinical studies have demonstrated neuroprotective efficacy comparable to Cerebrolysin and superior to Actovegin in rat models of acute and chronic brain ischemia. A systematic review of animal-derived nootropics noted that the limited number of eligible Cortexin studies precluded meta-analysis, though available data suggested potential efficacy with no safety concerns. The compound is generally well tolerated; the principal adverse events are injection site reactions (8 to 15 percent), headache (5 to 12 percent), dizziness (3 to 8 percent), and rare hypersensitivity reactions including anaphylaxis. This monograph reviews the composition, extraction methodology, and physicochemical properties of Cortexin; the pleiotropic molecular pharmacology; the pharmacokinetic limitations inherent to a heterogeneous peptide preparation; the clinical evidence base across cerebrovascular, traumatic, cognitive, and pediatric indications; sourcing and quality verification considerations; reconstitution and handling protocols; stack-interaction implications; adverse-event signal; and a structured comparative assessment of five neuroprotective alternatives against Cortexin on five competency standards.